6420 Annual Report 2005. qxd 28 4 06 17:44 Page 20 Board of Directors 01 01 Dr James Cavanaugh Dr James Cavanaugh 68 Chairman Chairman Dr Cavanaugh has been a member of Shires 02 Board since March 24, 1997 and Chairman Matthew Emmens since May 11, 1999.
He is a General Partner 01 02 Chief Executive Officer of HealthCare Partners, the General Partner of Healthcare Ventures, a venture capital 03 fund devoted to healthcare, Non-executive Angus Russell Chairman of Diversa Corporation and a Chief Financial Officer Non-Executive Director of MedImmune Inc. and Advancis Pharmaceutical Corporation.
04 He is a former President of SmithKline & Robin Buchanan French Laboratories, SmithKline Beecham Non-Executive Director Corporations clinical laboratory business, 03 04 and Allergan International, and served as 05 Deputy Assistant to the US President on the The Hon James Grant White House Staff.
Dr Cavanaugh is also Non-Executive Director Chairman of Shires Nomination Committee.
06 02 David Kappler Matthew Emmens 54 Non-Executive Director Chief Executive Officer Mr Emmens has been Shires Chief Executive 05 06 07 Officer and a member of the Board since Patrick Langlois March 12, 2003.
He began his career Non-Executive Director in international pharmaceuticals with Merck & Co, Inc. in 1974, where he held a wide 08 range of sales, marketing and administrative Ronald Nordmann positions.
In 1992, he helped to establish Non-Executive Director Astra Merck, a joint venture between Merck and Astra AB of Sweden, becoming President 09 and Chief Executive Officer.
In 1999, he 07 08 Barry Price joined Merck KGaA and established EMD Non-Executive Director Pharmaceuticals, the Companys US prescription pharmaceutical business.
He was later promoted to President of Merck KGaAs global prescription business, based in Germany.
Mr Emmens holds a degree in Business Management from Fairleigh Dickinson University.
He is also Chairman of Shires Executive and Portfolio 09 Review Committees.
20 Annual report and accounts for the year ended December 31, 2005 Shire plc 6420 Annual Report 2005. qxd 28 4 06 17:44 Page 21 03 06 08 Angus Russell 50 David Kappler 58 Ronald Nordmann 64 Chief Financial Officer and Non-Executive Director Non-Executive Director Executive Vice President of Global Finance Mr Kappler has been a member of Shires Mr Nordmann has been a member of Mr Russell has been Shires Chief Board since April 5, 2004.
He is currently Shires Board since December 23, 1999 and Financial Officer and a member of the Board also serving as Non-Executive Chairman previously served as a Non-Executive Director since December 13, 1999.
He also serves as of Premier Foods plc and as a Non-Executive of Roberts Pharmaceutical Corporation.
a Non-Executive Director of the City of London Director of Intercontinental Hotels Group He is also a Director of Neurochem Inc. Investment Trust plc.
Between 1980 and plc and HMV Group plc.
In addition, he and Par Pharmaceutical Companies, Inc. 1999, Mr Russell held a number of positions was a director of Camelot Group plc from Mr Nordmann is Co-President of Global Health of increasing responsibility at ICI, Zeneca and 1996-2002.
Mr Kappler retired from Cadbury Associates.
He has been a financial analyst AstraZeneca plc, including Vice PresidentSchweppes plc in April 2004 after serving in healthcare equities since 1971, holding Corporate Finance at AstraZeneca and Group as Chief Financial Officer since 1995. senior positions with Deerfield Management, Treasurer at Zeneca.
Mr Russell is a chartered He worked for the Cadbury Schweppes PaineWebber, Oppenheimer & Co. F accountant, having qualified with Coopers & group between 1965 and 1984 and rejoined Eberstadt & Co. and Warner-Chilcott Lybrand, and a fellow of the Association of the Company in 1989 following its acquisition Laboratories.
He holds a bachelors degree Corporate Treasurers.
He is also a member of of Trebor Group, where he was Financial from Johns Hopkins University and an MBA Shires Executive Committee and is Chairman Director.
Mr Kappler is a fellow of the from Fairleigh Dickinson University.
Mr of the Corporate Responsibility Committee.
Chartered Institute of Management Nordmann is also a member of Shires Audit, Accountants.
He is also Chairman Nomination and Remuneration Committees.
Robin Buchanan 53 09 Non-Executive Director 07 Dr Barry Price 62 Mr Buchanan has been a member of Shires Patrick Langlois 60 Non-Executive Director Board since July 30, 2003.
He also serves as a Non-Executive Director Dr Price has been a member of Shires Non-Executive Director of Liberty International Mr Langlois has been a member of Board since January 16, 1996 and is the plc.
Mr Buchanan is Senior Partner of the UK Shires Board since November 14, 2005.
operations and director of the global business He is also a Non-Executive Director of Coley He also serves as Chairman of Antisoma consultants Bain & Company Inc. and is a Pharmaceuticals Group, Inc. and was a Nonplc and Biowisdom Ltd. Dr Price worked member of that firms worldwide management Executive Director of Rhodia SA between for Glaxo for 28 years, where he held committee.
He previously worked for American December 2002 and April 2005.
Mr Langlois positions of increasing responsibility with Express International Banking Corporation in previously served as Vice Chairman of the the Companys research group.
Dr Price New York, McKinsey & Company, and Deloitte Management Board of Aventis S. A. Strasbourg, is also Chairman of Shires Remuneration & Touche, where he qualified as a chartered having been Group Executive Vice President Committee and a member of the Audit accountant FCA.
Mr Buchanan holds an MBA and Chief Financial Officer for several years.
with Distinction Baker Scholar from Harvard He also spent many years in senior financial Business School.
He is also a member of roles with the Rhone-Poulenc Group, including Shires Remuneration Committee.
three years as a member of the Executive Committee and Chief Financial Officer.
D. in Economics The Hon James Grant P. C, C. M, Q.
C 68 and a diploma in banking studies.
He is Non-Executive Director also a member of Shires Audit Committee.
Mr Grant has been a member of Shires Board since May 11, 2001 and previously served as a Director of BioChem Pharma Inc. since 1986.
He also sits on the boards of two Canadian public corporations and the boards of a number of other private corporations and not-for-profit foundations and councils.
He is a partner and Chair Emeritus with the law firm Stikeman Elliott in Montreal.
Mr Grant holds degrees in Arts and Law from McGill University.
He is also a member of Shires Nomination Committee.
Annual report and accounts for the 21 year ended December 31, 2005 Shire plc
